Full central neurokinin-1 receptor blockade is required for efficacy in depression: Evidence from orvepitant clinical studies

Journal of Psychopharmacology

Volumn 27, Issue 5, 2013, Pages 424-434

  Ratti, Emiliangelo ^a   Bettica, Paolo ^a   Alexander, Robert ^a   Archer, Graeme ^b   Carpenter, David ^c   Evoniuk, Gary ^c   Gomeni, Roberto ^c   Lawson, Erica ^c   Lopez, Monica ^c   Millns, Helen ^b   Rabiner, Eugenii A ^b   Trist, David ^a   Trower, Michael ^a   Zamuner, Stefano ^a   Krishnan, Ranga ^d   Fava, Maurizio ^e  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

clinical trials; Depression; neurokinin; receptor occupancy; substance P

Indexed keywords

NEUROKININ 1 RECEPTOR; ORVEPITANT; PLACEBO; RADIOLIGAND; UNCLASSIFIED DRUG; VOFOPITANT C 11;

ADULT; ANXIETY; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; CONVULSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FLATULENCE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SPONTANEOUS ABORTION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; NEUROKININ-1 RECEPTOR ANTAGONISTS; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY;

EID: 84876584503     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113480990     Document Type: Article

References (42)

1. Alper K, Schwartz KA, Kolts R, et al. Seizure incidence in psychopharmacological clinical trials: An analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007 ; 62: 345-354
2. Bergrsöm M, Fasth KJ, Kilpatrick G, et al. Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1- antagonists, GR203040 and GR205171 - PET studies in rhesus monkey. Neuropharmacology. 2000 ; 39: 664-670
3. Carletti R, Griffante C, Pozzato C, et al. NK1 receptor occupancy and anxiolytic-like effect of the novel NK1 receptor antagonist Vestipitant (GW597599) in gerbil. Eur Neuropsychopharmacol. 2005 ; 15 (S3). S539
4. Chappell P. Effects of CP-122,721, a selective NK-1 receptor antagonist, in patients with MDD. Presented at NCDEU June 12 2002, referenced in McLean S (2005): Do substance P and the NK1 receptor have a role in depression and anxiety?. Curr Pharm Des. 2002 ; 11: 1529-1154
5. De Felipe C, Herrero JF, O'Brien JA, et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature. 1998 ; 392: 394-397
6. Di Fabio R, Alvaro G, Griffante C, et al. Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide (Casopitant) as a new potent and selective NK1 receptor antagonist clinical candidate. J Med Chem. 2011 ; 54: 1071-1079
7. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004 ; 65: S27 - S32
8. Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry. 2006 ; 67: S14 - S21
9. Fava M, Iosifescu DV, Pedrelli P, et al. Reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire. Psychother Psychosom. 2009 ; 78: 91-97
10. Fava M, Rankin MA, Alpert JE, et al. An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. Psychother Psychosom. 1998 ; 67: 328-331
11. First MB, Spitzer RL, Gibbon M, et al Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York: Biometics Research, New York State Psychiatric Institute ; 2002 :
12. Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs. Peptides. 2005 ; 26: 1383-1393
13. GSK clinical study register (2009) NKI111364 - A 28-Day, polysomnographic and subjective assessment of Vestipitant (15 mg/day) for the treatment of primary insomnia in adult outpatients. Available at: http://www.gsk- clinicalstudyregister.com/result-comp-list.jsp?compound=vestipitant.
14. GSK Clinical Study Register (2010) NKG113211 - A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study evaluating the efficacy and safety of the neurokinin-1 receptor antagonist orvepitant (GW823296) in post traumatic stress disorder (PTSD). Available at: http://www.gsk-clinicalstudyregister.com/result-detail.jsp;jsessionid= 35C9B0DDC47899187FE1942674794DB9?protocolId=113211&studyId= 69BEE7E7-76F9-4595-8D33-AC49CFDABCF2&compound=orvepitant.
15. Guy W ECDEU Assessment Manual for Psychopharmacology - Revised. #ADM >76-338. Rockville MD: DHEW Pub ; 1976: 218-222.
16. Hargreaves R. Imaging substance P receptors (NK1) receptors in the living human brain using positron emission tomography. J Clin Psychiatry. 2002 ; 63: S18 - S24
17. Hesdorffer DC, Hauser WA, Olafsson E, et al. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol. 2006 ; 59: 35-41
18. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2006 ; 27: 1533-1539
19. Kalinichev M, Bradford A, Bison S, et al. Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat. Epilepsia. 2010 ; 51: 1543-1551
20. Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006 ; 59: 216-223
21. Khan AJ, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011 ; 72: 441-447
22. Khin NA, Chen Y-F, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry. 2011 ; 72: 464-472
23. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998 ; 281: 1640-1645
24. Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004 ; 29: 385-392
25. Labbate LA, Lare SB. Sexual dysfunction in male psychiatric outpatients: Validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Psychother Psychosom. 2001 ; 70: 221-225
26. Li X, Frye MA, Shelton RC. Review of pharmacological treatments in mood disorders and future directions for drug development. Neuropsychopharmacology. 2012 ; 37: 77-101
27. Liu H, Cao Y, Basbaum AI, et al. Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc Natl Acad Sci U S A. 1999a ; 96: 12096-12101
28. Liu H, Mazarati AM, Katsumori H, et al. Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Proc Natl Acad Sci U S A. 1999b ; 96: 5286-5291
29. Luthra SK, Osman S, Turton DR, et al. An automated system based on solid phase extraction and HPLC for the routine determination in plasma of unchanged [11C]-L-deprenyl; [11C]diprenorphine; [11C]flumazenil; [11C]raclopride; and [11C]Scherring-23390. J Labelled Comp Radiopharm. 1993 ; 32: 518-520
30. Posner K, Brown GK, Stanley B, et al. The Columbia Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 ; 168: 1266-1277
31. Ratti E, Bellew K, Bettica P, et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol. 2011 ; 31: 727-733
32. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 ; 70: 326-333
33. Robinson P, Garza A, Weinstock J, et al. Substance P causes seizures in neurocysticercosis. PLoS Pathog. 2012 ; 8: e1002489
34. Roehrs T, Lamphere J, Paxton C, et al. Temazepam's efficacy in patients with sleep onset insomnia. Br J Clin Pharmacol. 1984 ; 17: 691-696
35. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 ; 163: 1905-1917
36. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 ; 54: 573-583
37. Santarelli L, Gobbi G, Debs PC, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci U S A. 2001 ; 98: 1912-1917
38. Spinks TJ, Jones T, Bloomfield PM, et al. Physical characteristics of the ECAT EXACT3D positron tomograph. Phys Med Biol. 2000 ; 45: 2601-2618
39. Targum SD, Pollack MH, Fava M. Redefining affective disorders: relevance for drug development. CNS Neurosci Ther. 2008 ; 14: 2-9
40. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988 ; 45: 742-747
41. Zachrisson O, Lindefors N, Brené S. A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity. Brain Res Mol Brain Res. 1998 ; 60: 291-295
42. Zamuner S, Rabiner EA, Fernandes SA, et al. A pharmacokinetic PET study of NK1 receptor occupancy. Eur J Nucl Med Mol Imaging. 2012 ; 39: 226-235